05:49 AM EDT, 04/21/2026 (MT Newswires) -- Elicera Therapeutics (ELIC.ST) is targeting to raise 72.8 million kronor through a rights issue of up to 24,267,772 new shares with preferential rights for existing shareholders.

Under the 3 krona-per-share rights issue, existing shareholders will receive one subscription right per share held, with every two rights entitling them to subscribe for one new share, according to a Tuesday release. The subscription period will run from May 15 to May 29.

The clinical stage immuno-oncology company earmarked proceeds to support its clinical trials, including the phase 1/2a Carma trial assessing ELC-301 for patients with relapsed or refractory B-cell lymphoma and to advance preparations for the planned phase I/Ib clinical trial of ELC-401, as well as for general company needs.